Wetzikon

Researchers are evaluating the effects of a 12-week exergaming training program in people with major neurocognitive disorders MNCD living in long-term care facilities. This pilot randomized controlled trial aims to understand how exergaming impacts gait speed, cognitive and motor functions, depressive symptoms, quality of life, physical activity, and sleep in these residents. The study focuses on non-drug therapies combining physical exercise and cognitive stimulation, addressing a public health priority where no current treatments can halt disease progression. Participants will either engage in an active dance video game using the Dividat Senso platform for 15 minutes, three times a week, over 12 weeks or receive usual care consisting of standard activities and customized support. The exergaming involves stepping on directional arrows guided by a large screen with auditory, visual, and sensory feedback. Usual care includes meal services and various social and physical activities. The trial compares these two groups to assess the interventions impact. During the study, researchers will measure physical performance using the Short Physical Performance Battery and cognitive function with the Montreal Cognitive Assessment, among other scales assessing depression, neuropsychiatric symptoms, sleep quality, daily living activities, and quality of life. Physical activity and sleep will be monitored with motion and contactless sensors. Assessments occur at the start and after 12 weeks. Statistical analysis will evaluate changes between baseline and post-intervention outcomes, with safety and efficacy monitored throughout the trial period.

This research aims to evaluate the long-term outcomes, performance, and ongoing safety of the BIOMONITOR III and its possible successors in everyday clinical use. It focuses on patients with conditions such as tachycardia, atrial fibrillation, syncope, bradycardia, or cryptogenic stroke. The study is designed as an observational registry, allowing additional scientific investigations with minimal extra effort for participants and study sites. Participants will receive a BIOTRONIK Implantable Cardiac Monitor ICM and will use the CardioMessenger device to support the BIOTRONIK Home Monitoring system. The registry monitors patients under routine clinical care without introducing experimental treatments or interventions. Data collection includes the insertion procedure and success rate of the device, as well as the time taken to reach a relevant diagnosis starting from device implantation. Throughout the study, participants will be observed during their regular clinical care visits. Researchers will collect information on device performance, safety, and diagnostic timelines. The study will continue until August 30, 2027, tracking patient outcomes over this extended period. Participation involves consenting to the use of home monitoring technology and agreeing to data collection related to the implanted device and clinical events.